The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials-Reference-Cited by-同舟云学术

The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials

Published:2018-09-28 Issue:2 Volume:33 Page:546-549
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Klausen Tobias W.,Gregersen Henrik,Abildgaard Niels,Andersen Niels Frost,Frølund Ulf Christian,Gimsing Peter,Helleberg Carsten,Vangsted Annette J.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-018-0272-0.pdf

Reference15 articles.

1. Gimsing P, Holmström MO, Wirenfelt Klausen T, Frost Andersen N, Gregersen H, Pedersen RS, et al. The Danish national multiple myeloma registry. Clin Epidemiol. 2016;8:583–7.

2. Gregersen H, Vangsted AJ, Abildgaard N, Andersen NF, Pedersen RS, Frolund UC, et al. The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study. Cancer Med. 2017;6:1807–16.

3. Zweegman S, van der Holt B, Mellqvist U-H, Salomo M, Bos GMJ, Levin M-D, et al. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Blood. 2016;127:1109–16.

4. Abildgaard N, Vangsted A, Gregersen H, Andersen N, Pedersen R, Plesner T, et al. Continued improvement in overall survival in elderly multiple myeloma patients after 2008; a population based study from the Danish Multiple Myeloma Registry. Clin Lymphoma, Myeloma Leuk. 2015;15:e189.

5. Sonneveld P, Goldschmidt H, Rosiñol L, Bladé J, Lahuerta JJ, Cavo M, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of Phase III Randomized, Controlled Trials. J Clin Oncol. 2013;31:3279–87.

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nationwide implementation of lenalidomide maintenance in multiple myeloma: A retrospective, real‐world study;eJHaem;2024-03-27

2. Bendamustine, prednisone and bortezomib (BPV) induction therapy prior autologous stem cell transplantation (ASCT) in 135 newly diagnosed multiple myeloma patients: comparison between patients with normal and impaired renal function;2023-12-11

3. Outcomes of Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma According to Clinical Trials Enrollment: Experience of a Single Institution;Cancers;2023-11-02

4. Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients;Targeted Oncology;2023-09

5. Real‐world outcomes upon second‐line treatment in patients with chronic lymphocytic leukaemia;British Journal of Haematology;2023-03-10